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Epilepsy is a disorder of the brain characterized by an enduring predisposition to gen-
erate epileptic seizures. In the last two decades, numerous gene defects underlying 
different forms of epilepsy have been identified with most of these genes encoding ion 
channel proteins. Despite these developments, the etiology of majority of non-familial 
epilepsies has no known associated genetic mutations and cannot be explained by 
defects in identified ion channels alone. We hypothesize that de novo formation of ion 
channels by naturally unfolded proteins (NUPs) increases neuronal excitability. Altered 
ionic homeostasis may initiate/contribute to cellular cascades related to epileptogenesis 
in susceptible individuals. Here, we consider two small proteins, namely, α-synuclein and 
stefin B, as prototypical candidates to illustrate the underlying mechanism(s). Previous 
work points to an association between epilepsy and α-synuclein or stefin B, but the 
mechanism(s) underlying such association remains elusive. We review the evidence to 
link the structure–function of these proteins with disease processes. Epigenetic mech-
anisms unrelated to altered DNA sequence(s) that may affect epileptogenesis include 
transcriptional or posttranscriptional regulation. Such epigenetic mechanisms or their 
combination(s) enhance the levels of these proteins and as a result the ability to form 
annular structures, which upon incorporation into membrane form novel ion channels 
and disturb intracellular ion homeostasis. Alternative epigenetic mechanisms may 
change amyloidogenic proteins by posttranslational modifications, thereby increasing 
their propensity to form channels. Further research elucidating the details about the 
formation of ion channels through these mechanisms and their role in epileptogenesis 
may define new molecular targets and guide the development of new drug targets.
Keywords: epilepsy, ion channels, α-synuclein, stefin B, epigenetic mechanisms, posttranslational modifications, 
microrna, parkinson’s disease
introdUCtion
Epilepsy is a group of neurological diseases characterized by recurrent episodes of convulsive sei-
zures, sensory disturbances, abnormal behavior, loss of consciousness, or a combination of these 
signs and/or symptoms. As defined by International League Against Epilepsy, epilepsy is a disorder 
of the brain characterized by an enduring predisposition to generate epileptic seizures that are more 
than 24 h apart (1). Although epilepsy can manifest itself in a number of different ways, it shares the 
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common feature of persistently increased neuronal excitability 
and spontaneous seizure generation.
Epilepsy is a widespread disease, being the fourth most com-
mon neurological disorder in the United States after migraine, 
stroke, and Alzheimer’s disease. Approximately 150,000 new 
cases are diagnosed in the United States annually, and 1 in 26 
individuals will develop epilepsy at some point in their lifetime. 
The total indirect and direct cost of epilepsy in the United States 
is estimated to be $15.5 billion per year (2).
Despite recent advancements in epilepsy treatment, currently 
available interventions and antiepileptic drugs (AEDs) are not 
effective in over 30% of patients (3). The current state of known 
mechanisms of epilepsy and the range of available treatments 
suggest additional pathways and mechanisms responsible for 
currently intractable cases of epilepsy. This underscores the 
importance of more research needed to better understand the 
underlying disease mechanisms and identify novel drug targets 
or treatment strategies (4). We present available evidence for the 
potential role of epigenetic mechanisms and certain naturally 
unfolded proteins (NUPs) that may create pores in cell mem-
branes and contribute to dysregulated ion flows that characterize 
electric discharges.
MeCHanisM oF idiopatHiC epiLepsy is 
not CLear
Genetic mutations play an important etiological role in the 
development of epilepsy in hereditary cases of this disease (5–10). 
However, the mechanism of seizures in a significant proportion 
of patients remains unexplained. Such individuals include those 
with traumatic brain injury (TBI), intracranial infection, brain 
tumor, stroke, vascular disturbances, intoxication, or chemical 
imbalance. Additionally, there exists a large cohort of patients 
who may not be accounted for under these categories of associated 
conditions. Development of such idiopathic epilepsies represents 
a spectrum of changes from initial injury to established disease 
state. These changes include molecules to pathways and single cell 
structure to cellular network organization.
Epileptogenesis summarizes interactive changes in cel-
lular processes that culminate in the development of a epilepsy. 
Epileptogenesis spans over a period without overt manifestation 
of symptoms, while subcellular structural and functional altera-
tions may occur. These changes include neuronal death, axonal 
growth and sprouting, altered inter neuron connections, and 
reorganization of neuronal networks. Temporal connections 
among these changes or their relationships with the onset of 
neuronal hyperexcitability and spontaneous seizures are not well 
understood. Cellular events during epileptogenesis may include 
epigenetic mechanisms that modify processing of RNA and/or 
proteins leading to non-familial epilepsy.
deFeCts in ioniC CHanneLs CaUse 
seiZUres
Common to all types of epilepsy is an uncontrolled electrical 
discharge from neurons. Therefore, ion channels are recognized 
as the key target in understanding the mechanism and treatment 
of epilepsy. Ion channels constitute a unique group of cellular 
proteins, which are highly significant in excitable cells due to 
their role in generation and regulation of electrical discharges. 
Ion channels are formed by multimeric arrangements of iono-
phoric membrane proteins. These proteins organize to provide 
a passageway (channel) across the membrane connecting its 
outer and inner sides. Such channels permit a controlled flow 
of ions across the two sides of membrane regulating the resting 
potential, action potential, and other electrical properties of the 
membrane while modulating cellular responses to the micro-
environment. Ion channels also contribute to regulated cellular 
responses to changes in cellular environment and maintain ion 
homeostasis.
Ion channels constitute the most favored class of targets for 
currently available treatments. Most AEDs have been designed 
to target ion channels and transporters and one that affects 
synaptic vesicle protein Sv2a with a goal to favor inhibition of 
over excitation and thereby decrease or prevent seizure activity/
frequency (11–13). These include AEDs targeting voltage-gated 
sodium channels, voltage-gated calcium channels, voltage-gated 
potassium channels, the GABA system and receptor agonists, 
glutamate receptor antagonists, and other inhibitory neuro-
transmitters. Additionally, currently used AEDs reduce neuronal 
hyperexcitability and thereby suppress epileptic seizures.
Despite these developments, available AEDs have had only 
limited success. Current drugs, more than 20, are employed solely 
to suppress seizures. Seizures can be effectively controlled in ~70% 
of patients, whereas 30% remain refractory to drug treatment 
pointing to alternative mechanisms and significant unmet need 
for effective intervention. Second, the existing armamentarium 
does not affect the comorbidities of epilepsy and does not prevent 
the development and progression of epileptogenesis (14–16). By 
and large, the entire process of epileptogenesis offers a number of 
targets but remains underappreciated.
Altered ion channel function is used as a leading reason of 
the etiology of seizures and epilepsy. However, lack of explana-
tion for disease manifestation in the absence of gene mutations 
represents gap in our understanding of the mechanism(s) of the 
disease. Thus, altered ion homeostasis while ion channels are not 
genetically altered remains an unanswered question. With these 
problems in view, a better understanding of the events of epilep-
togenesis may lead to prevention of seizures, early diagnoses, and 
treatment of epilepsy in those patients who do not benefit from 
current treatments.
epiGenetiC MeCHanisMs ControL 
Gene FUnCtion WitHoUt dna 
MUtation
Recent developments show that DNA may undergo multiple 
enzymatic modifications, which are used in epigenetic regula-
tion of gene expression. Epigenetics is the study of alterations in 
the function of genes that do not involve changes in the DNA 
sequence itself, but rather its expression. Epigenetic mechanisms 
involve the transfer of information arising from short-lived 
FiGUre 1 | examples of various aggregated states of naturally 
unfolded proteins.
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cellular signals and changes in neuronal activity into lasting 
effects on gene expression.
Rapid exponential advances in high-throughput DNA 
sequencing technologies convincingly demonstrate that a con-
siderable number of epileptic patients do not carry mutations in 
genes encoding ion channels or related genes, thereby implying 
alternative mechanisms involved. Therefore, it is important to 
learn what other molecular mechanisms, not associated with 
alterations in genome sequence, may contribute to the develop-
ment of epilepsy.
Importantly, from the viewpoint of treatment, epigenetic 
changes are potentially reversible and therefore may form the 
basis for the future development of efficient therapies. Major 
epigenetic mechanisms include DNA methylation, histone 
modification, and microRNA-driven posttranscriptional regula-
tion of gene expression. Methylation-dependent gene silencing is 
currently one of the most thoroughly investigated mechanisms 
for regulation of gene expression (17–21).
epiLepsy sUCH as tBi-indUCed 
epiLepsy May Be CaUsed By 
epiGenetiC MeCHanisMs
Epigenetics may explain the process of epileptogenesis such as 
posttraumatic epilepsy (PTE) in TBI. Although the study of 
epigenetic mechanisms of PTE is an emerging area of inves-
tigation, the results of several studies point to the importance 
of this approach in understanding the consequences of TBI 
in general and PTE in particular. For example, Gao et al. (22) 
demonstrated that TBI may cause epigenetic changes in an 
animal model of TBI. Specifically, alterations in hippocampal 
CA3 histone H3 acetylation and methylation occur hours to 
days following injury. In another study, global hypomethylation 
was observed after TBI in a subpopulation of reactive microglia/
macrophages (23). An important, but not completely understood 
clue to understanding of TBI-induced epigenetic alterations is 
the finding that TBI causes relocation of DNA-methyltransferase 
1—enzyme catalyzing sequence-specific DNA methylation (24). 
However, a detailed mechanism underlying this translocation 
and its connection with methylation pattern changes require 
further studies.
idiopatHiC ForMs oF epiLepsy May 
Be assoCiated WitH tHe ForMation 
oF neW ion CHanneLs By nUps
Posttraumatic epilepsy is just one example of the development 
of epilepsy without an underlying, inherited mutation(s). Below 
we discuss another example based on the formation de novo ion 
channels from amyloidogenic proteins, which may be responsible 
for non-familial cases of epilepsy.
In addition to the heterogeneous family of authentic ion 
channels, a group of naturally unfolded intrinsically unstruc-
tured proteins can form novel ion channels as a result of their 
conformational transitions. This group consists of the so-called 
NUPs, which can aggregate to form oligomers and amyloid 
structures. These proteins may accumulate as large amyloid 
deposits and inclusions in Alzheimer’s disease (amyloid beta, 
Aβ) (25–27), Parkinson’s disease (α-synuclein), and prion 
disease (prion protein, PrP) (28–33). Alternatively, NUPs can 
form annular protofibrils that can act as ion channels increasing 
membrane conductance (34, 35) (Figure 1).
The formation of ion channels from NUPs is a well-known 
phenomenon (35–37). However, the role of such channels 
generated under de novo conditions has not been investigated to 
explore the development of epilepsy.
Ion channel-like membrane pores may be ion-specific or non-
selective with regard to ions. Amyloidogenic proteins generally 
produce rather large pores (3–10 nm in diameter), which are rela-
tively non-selective for ion traffic (38, 39). However, well-defined 
sizes and morphologies have been found for some amyloid pores 
such as those generated from α-synuclein (34).
α-synUCLein and steFin B are 
Candidate pore-ForMinG proteins
We present below several observations showing that proteins 
forming annular protofibrils and thus affecting membrane 
conductance are associated with epilepsy. We will discuss here 
two NUPs that can form membrane pores or channels, namely, 
α-synuclein and stefin B. These proteins have several similar 
properties, which may determine their ability to form new ionic 
channels and therefore a role in epilepsy:
 (a) These are small size proteins that can readily interact with 
membranes to form oligomers, annular structures, and 
amyloid fibrils (40, 41, 42).
 (b) Their properties are regulated by posttranslational modifica-
tions (43, 44).
 (c) A lack of cysteine prevents formation of disulfide bonds in 
both proteins (45–47).
 (d) Expression of α-synuclein and stefin B is regulated by epi-
genetic mechanisms, such as methylation/demethylation of 
regulatory regions in their genes (48, 49).
 (e) Both proteins lack export signal sequences; however, they 
are detectable in both intracellular and extracellular spaces 
(45, 47).
FiGUre 2 | Binding of β-lactam antibiotic ceftriaxone to α-synuclein 
C-terminus. (a) Chemical structure of ceftriaxone. (B) Schematic 
organization of human α-synuclein with localization of known missense 
mutations indicated by small arrows. N-terminal domain contains all 
missense mutations, predisposing to α-synuclein aggregation. These 
mutations include three well-characterized and carefully studied missense 
mutations: A53T (51), A30P (52), and E46K (53). The toxicity of these mutant 
forms of α-synuclein may be due to their enhanced aggregation into 
oligomers and amyloid fibrils. Two recently identified mutations, which are not 
yet well investigated, H50Q (54) and G51D (55), may have an important effect 
on α-synuclein properties, since they add new potential phosphorylation sites 
to the first N-terminal helix (56). Phosphorylation of Ser129 enhances 
aggregation of α-synuclein (57). Y125, Y133, and Y136—tyrosine residues, 
which are a part of ceftriaxone-binding site (58). MTS, mitochondria-targeting 
sequence (42). Modified from Ghanizadeh and Berk (59).
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Conversely, there is a difference between α-synuclein and stefin 
B with regard to their association with epilepsy. Several missense 
mutations in stefin B are linked to epilepsy (50), whereas rare mis-
sense mutations in α-synuclein gene (Figure 2B) are associated 
with Parkinson’s disease (51–53).
No data about association of mutations in α-synuclein gene 
with epilepsy are currently available.
Mechanisms that link Parkinson’s disease with epilepsy require 
further exploration but are beyond the scope of this review.
α-synuclein
α-Synuclein is a major structural component of intracellular 
protein inclusions or Lewy bodies that constitute a pathological 
hallmark of Parkinson’s disease. Furthermore, α-synuclein is 
implicated in multiple system atrophy, dementia with Lewy 
bodies, and other diseases (37, 60). However, the exact mecha-
nism of α-synuclein toxicity and its role in healthy cells and in 
diseases remain elusive. While a direct link between mutations 
in α-synuclein and epilepsy has not been described so far, several 
findings point to an association of α-synuclein with this disease. 
These include the following:
 (a) Patients with α-synuclein gene multiplication have seizures. 
Although a rare event, multiplication of α-synuclein gene 
resulting in its abundance in the central and peripheral nerv-
ous system generates different disease phenotypes, including 
seizures and myoclonus (61).
 (b) α-Synuclein concentration is elevated in the CSF and 
serum of epileptic patients (62), as well as in a mouse 
model of epilepsy (63) (see details in Section “α-Synuclein 
Concentration Is Changed in Body Fluids of Epileptic 
Patients”).
 (c) β-Lactam antibiotics, such as ceftriaxone, known to reduce 
frequency of seizures bind to α-synuclein and inhibit its 
aggregation (58).
We outline the physicochemical characteristics of α-synuclein, 
which render this molecule capable of forming new ion channels.
Structure and Functions of α-Synuclein
α-Synuclein is an NUP of the synuclein family, which consists 
of three members, namely, α-, β-, and γ-synuclein (42, 47). 
α-Synuclein is a small protein (140 amino acids, 14  kDa) pre-
dominantly expressed in CNS neurons. α-Synuclein amino acid 
sequence can be subdivided into three domains: N-terminal, 
amphipathic repeat region (residues 1–60), the so-called non-
amyloid beta component domain (NAC-region, residues 61–95), 
and C-terminal acidic domain (residues 96–140) (Figure 2).
In physiological solutions, α-synuclein is characterized by a 
lack of rigid, well-defined structure and exists predominantly in 
unfolded or intrinsically disordered form (29, 37, 60). However, 
α-synuclein possesses high conformational plasticity and is able 
to adopt a series of different conformations depending on the 
environmental conditions and binding partners (64). Importantly, 
formation of oligomers and aggregates is concentration depend-
ent, increases at elevated α-synuclein expression, underlies a toxic 
gain of function, and may lead to the development of pathology 
(65–67).
α-Synuclein Forms Annular Protofibrils Increasing 
Membrane Permeabilization
Lashuel et  al. (34) described the ability of α-synuclein to form 
annular protofibrils, which might incorporate into membrane, 
form pores, and disturb membrane permeabilization leading to 
cell dysfunction and even cell death. This pathogenic–protofibril 
hypothesis was supported by biophysical studies of not only 
α-synuclein but also other amyloidogenic proteins, e.g., Aβ 
suggesting a putative common mechanism in Parkinson’s and 
Alzheimer’s diseases (34).
Protofibrillar α-synuclein is able to induce vesicle permeabili-
zation (37), while helical α-synuclein forms highly conductive ion 
channels (35). Ding et al. (68) described production of annular 
α-synuclein protofibrils when spherical protofibrils were incu-
bated in solution or bound to brain-derived membranes.
α-Synuclein Concentration Is Changed in Body 
Fluids of Epileptic Patients
Increased α-synuclein concentration in serum, CSF, and specific 
brain regions has been described in epileptic patients as well as 
in an animal model of epilepsy. Li et al. (63) used the pilocarpine 
mouse model of temporal lobe epilepsy to screen the proteome 
and found a statistically significant increase in α-synuclein 
expression in temporal lobe epilepsy. In another study, Rong 
et al. (62) found elevated concentration of total α-synuclein in 
the CSF and serum of the epilepsy patients, as compared to the 
FiGUre 3 | putative mechanisms affecting α-synuclein ability to form 
ion channels. Organization of human α-synuclein genes (71). Blue (coding) 
and red (untranslated) exons are shown in boxes; introns are shown as 
interrupted horizontal lines. Epigenetic mechanism: methylation of CpG 
islands and microRNA binding to 3′-UTR region of the gene regulate 
α-synuclein expression on transcriptional and posttranscriptional level, 
respectively. Phosphorylation (P) of α-synuclein regulates its aggregation.
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control. The authors concluded that α-synuclein content in the 
serum and CSF may facilitate the identification of intractable 
epilepsy and serve as a valuable prognostic marker in the clini-
cal assessment. Yang et al. (69) described aberrant expression of 
α-synuclein in hippocampus from patients with mesial temporal 
lobe epilepsy. Thus, α-synuclein is increased in body fluids of 
epileptic patients and can be used as an essential biological 
marker in epilepsy.
β-Lactam Antibiotics with Antiseizure Activity Inhibit 
α-Synuclein Aggregation
β-Lactam antibiotics, e.g., ceftriaxone or cefixime, possess 
neuroprotective effect, exhibit excellent blood–brain barrier 
penetration, and suppress posttraumatic seizures. Ceftriaxone 
treatment ameliorates both seizure frequency and duration (70). 
Importantly, these antiseizure substances bind to α-synuclein and 
affect its aggregation (58).
Epigenetic Mechanisms Affecting α-Synuclein Ability 
to Form Ion Channels
Several mechanisms may affect α-synuclein ability to form ion 
channels (Figure 3).
α-Synuclein aggregation is a concentration-dependent process 
and therefore may be affected by the level of its expression. 
A  number of mechanisms control the level of α-synuclein 
expression, including transcriptional regulation by methylation/
demethylation of regulatory regions in α-synuclein gene (48, 49) 
(mechanism #1). Another mechanism controlling α-synuclein 
expression is posttranscriptional regulation by microRNAs (43) 
(mechanism #2). Finally, α-synuclein posttranslational modifica-
tion, e.g., phosphorylation predisposes it to conformational 
changes and aggregation (44, 57) (mechanism #3) and may affect 
its pore formation capacity. In addition to its ability to form 
annular and ring-like structures (Figure  1) functioning as ion 
channels, α-synuclein also interacts with intrinsic ion channels 
that build from other proteins and changes their properties (72). 
This feature of α-synuclein may also change conductance through 
alteration of membrane permeability. Several mechanisms may 
affect the ability of α-synuclein to form ion channels (Figure 3).
stefin B
Structure and Function of Stefin B
Human stefin B is a member of cystatin superfamily consisting of 
single-chain protein, which is composed of 98 amino acid residues 
with a molecular mass of 11 kDa (45). Stefin B is a neutral protein 
able to form a dimer stabilized by non-covalent forces. Similar 
to other members of the cystatin superfamily, stefin B is revers-
ible and competitive inhibitor of cysteine proteases, particularly 
cathepsin L and cathepsin S. Stefin B is widely distributed among 
different cell types and tissues. Although it lacks an export signal 
sequence and is generally thought to function intracellularly, it 
has also been found in extracellular fluid (45). Stefin B plays a 
role in protecting cytosolic and cytoskeleton proteins against the 
cysteine proteases. Besides protease inactivation, stefin B binds 
other proteins forming a multiprotein complex, which might 
contribute to the disease in patients with progressive myoclonic 
epilepsies.
Eight mutations in the stefin B gene have been reported to 
associate with progressive myoclonic epilepsy of Unverricht–
Lundborg type (EPM1). Most of the disease alleles harbor an 
unstable expansion of at least 30 copies of a normally polymorphic 
12-nucleotide, dodecamer repeat located in the promoter region 
of the stefin B gene. Three reported EPM1 mutations affect splice 
sites, two result in amino acid changes, and two predict truncated 
proteins due to a nonsense or frameshift mutation (45).
Stefin B Forms Annular Protofibrils Increasing 
Membrane Permeabilization
Although the function of stefin B in the pathogenesis of epilepsy 
is not completely understood, experiments in vitro show that two 
missense mutants G50E and Q71P aggregate to a much greater 
extent than the wild-type (WT) protein (50).
Calcein release results and electrophysiological measurements 
demonstrate that both WT stefin B and the Y31, but not G4R 
mutant isoform, are able to form pores in planar lipid bilayers, 
thereby increasing membrane permeabilization (41). Importantly, 
there is a clear distinction between oligomer size and toxicity. In 
the case of WT stefin B, the monomers, dimers, and tetramers 
of WT stefin B are not toxic, while higher species starting with 
hexamers and dodecamers acquire toxicity (73).
Mechanisms Affecting the Formation of Ion Channels 
by Stefin B
Mechanisms affecting stefin B expression and regulating its 
ability to form ion channels are similar to those described for 
α-synuclein. Stefin B epigenetic mechanisms regulating its 
expression through DNA methylation are investigated in several 
diseases, including breast, pancreatic, brain, and lung cancer (46).
Patients with progressive epilepsy of the Unverricht–Lundborg 
type are characterized by myoclonic seizures and ataxia. The 
majority of such patients carry repeat expansions of a dodecamer 
with high GC content in the promoter region of the stefin B gene 
(74). Although the regulatory role of these dodecamer has not been 
investigated in detail, these GC stretches are the site of methyla-
tion/demethylation regulating the expression of the downstream 
gene. These findings suggest that DNA methylation-dependent 
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epigenetic mechanisms may play a central role in the regulation 
of stefin B expression.
The knowledge of epigenetic mechanisms implicated in the 
development of epilepsy provides a conceptual and mechanistic 
framework for the future development of epigenetic therapies 
tailored to prevent epilepsy (antiepileptogenic) or its progression 
(disease modifying).
disCUssion and ConCLUsion
Numerous causative mutations have been detected and char-
acterized in familial cases of epilepsy, and the details about 
genetic mechanisms underlying this disease are accumulating. In 
contrast, the underlying mechanisms in a significant proportion 
of epilepsy patients remain unknown, thereby hampering treat-
ment and drug development. We propose novel biochemical and 
epigenetic mechanisms, which provide alternative explanation 
for the development of idiopathic epilepsy. We consider here that 
certain NUPs may form new channels as a result of epigenetic 
modification(s) on transcriptional (methylation/demethylation 
of regulatory regions), posttranscriptional levels (microRNA-
driven mechanism), or due to posttranslational modifications 
(phosphorylation, glycosylation of protein, etc.). We provide 
evidence that NUPs can bind to plasma membrane and form new 
ion channels that can alter intracellular ion homeostasis.
A role of NUPs in the formation of new channels, which 
may disrupt membrane conductance, disturb ion homeostasis, 
and ultimately lead to seizures, is based on several experimental 
findings:
 (a) α-Synuclein and other intrinsically unstructured proteins 
form annular protofibrils or pores, which incorporate into 
membrane and act as ion channels increasing membrane 
permeabilization (34, 35, 37).
 (b) Patients with α-synuclein genetic defects have seizures (61).
 (c) β-Lactam antibiotics, such as ceftriaxone, known to reduce 
frequency of seizures bind to α-synuclein and inhibit its 
aggregation (58).
 (d) α-Synuclein concentration is elevated in the CSF and 
serum of epileptic patients (62) and in a mouse model of 
epilepsy (63).
Each of these findings individually may be considered only as 
indirect evidence. However, considering the molecular nature of 
α-synuclein in the light of an increase in the frequency of seizures 
in parallel with its levels provides a strong argument in support 
of a potential role of α-synuclein in epilepsy. Long duration of 
epileptogenesis provides sufficient time for manifestation of 
several possible epigenetic mechanisms, which may trigger the 
formation of novel ion channels. Alternatively, formation of novel 
ion channels and changes in membrane permeabilization may 
lead to epigenetic changes. 
In fact, the proposed mechanism for ion channel formation 
may be widely distributed in the cell than currently imagined. 
In addition to plasma membrane, formation of ion channels 
may also be evident in intracellular organelles, e.g., membranes 
of mitochondria and lysosomes. Therefore, many details of epi-
genetic mechanisms remain to be determined in order to better 
understand the causes of sporadic epilepsy and their specific 
treatments.
Several alternative hypotheses have been proposed previously 
to explain the development of non-familial forms of epilepsy due 
to epigenetic mechanisms. Among them is an increased activity 
of DNA methylating enzymes leading to hypermethylation of 
DNA (75–79). Another proposed mechanism implicates histone 
modifications that involve the addition or removal of methyl or 
acetyl groups during epileptogenesis (21). Recently, Boison (16) 
proposed that adenosine and glycine may regulate epigenetic 
mechanisms of epileptogenesis. Other putative mechanisms of 
epileptogenesis are discussed in recent publications (80–83). Our 
hypothesis is different from those mentioned here. We believe 
that while acquired epilepsy is associated with ion channels, 
its etiology and pathophysiology are likely determined by the 
de novo formation of channels from NUPs.
The knowledge of new epigenetic mechanisms implicated 
in the development of epilepsy will provide a conceptual and 
mechanistic framework for future development of therapies 
tailored to prevent epilepsy (antiepileptogenic) or its progression 
(disease modifying).
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